USRE38506E1 - Potent inducers of terminal differentiation and methods of use thereof - Google Patents

Potent inducers of terminal differentiation and methods of use thereof Download PDF

Info

Publication number
USRE38506E1
USRE38506E1 US10004411 US441101A USRE38506E1 US RE38506 E1 USRE38506 E1 US RE38506E1 US 10004411 US10004411 US 10004411 US 441101 A US441101 A US 441101A US RE38506 E1 USRE38506 E1 US RE38506E1
Authority
US
Grant status
Grant
Patent type
Prior art keywords
group
hz
ml
compound
ch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10004411
Inventor
Ronald Breslow
Paul A. Marks
Richard A. Rifkind
Branko Jursic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan-Kettering Institute for Cancer Research
Columbia University of New York
Original Assignee
Sloan-Kettering Institute for Cancer Research
Columbia University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/05Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/06Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/15Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Abstract

The present invention provides the compound having the structure:
Figure USRE038506-20040420-C00001
wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
The present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition and a therapeutically acceptable amount of the compound above.

Description

BACKGROUND OF THE INVENTION

Throughout this application various publications are referenced by arabic numerals within parentheses. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

Cancer is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms which normally govern proliferation and differentiation. For many years there have been two principal strategies for chemotherapeutic treatment of cancer: a) blocking hormone-dependent tumor cell proliferation by interference with the production of peripheral action of sex hormones; and b) killing cancer cells directly by exposing them to cytotoxic substances, which injure both neoplastic and normal cell populations.

Relatively recently, cancer therapy is also being attempted by the induction of terminal differentiation of the neoplastic cells (1). In cell culture models differentiation has been reported by exposure of cells to a variety of stimuli, including: cyclic AMP and retinoic acid (2,3), aclarubicin and other anthracyclines (4).

There is abundant evidence that neoplastic transformation does not necessarily destroy the potential of cancer cells to differentiate (1,5,6). There are many examples of tumor cells which do not respond to the normal regulators of proliferation and appear to be blocked in the expression of their differentiation program, and yet can be induced to differentiate and cease replicating. A variety of agents, including some relatively simple polar compounds (5,7-9), derivatives of vitamin D and retinoic acid (10-12), steroid hormones (13), growth factors (6,14), proteases (15,16), tumor promoters (17,18), and inhibitors of DNA or RNA synthesis (4,19-24), can induce various transformed cell lines and primary human tumor explants to express more differentiated characteristics.

Early studies by the present inventors identified a series of polar compounds that were effective inducers of differentiation in a number of transformed cell lines (8,9). Of these, the most effective inducer, was the hybrid polar/apolar compound N,N′-hexamethylene bisacetamide (HMBA) (9). The use of this polar/apolar compound to induce murine erythroleukemia cells (MELC) to undergo erythroid differentiation with suppression of oncogenicity has provided a useful model to study inducer-mediated differentiation of transformed cells (5,7-9). HMBA-induced MELC terminal erythroid differentiation is a multistep process. Upon addition of HMBA to MELC (745A-DS19) in culture, there is a latent period of 10 to 12 hours before commitment to terminal differentiation is detected. Commitment is defined as the capacity of cells to express terminal differentiation despite removal of inducer (25). Upon continued exposure to HMBA there is progressive recruitment of cells to differentiate. The present inventors have reported that MELC cell lines made resistant to relatively low levels of vincristine become markedly more sensitive to the inducing action of HMBA and can be induced to differentiate with little or no latent period (26).

HMBA is capable of inducing phenotypic changes consistent with differentiation in a broad variety of cells lines (5). The characteristics of the drug induced effect have been most extensively studied in the murine erythroleukemia cell system (MELC) (5,25,27,28). MELC induction of differentiation is both time and concentration dependent. The minimum concentration required to demonstrate an effect in vitro in most strains is 2 to 3 mM; the minimum duration of continuous exposure generally required to induce differentiation in a substantial portion (>20%) of the population without continuing drug exposure is about 36 hours.

The primary target of action of HMBA is not known. There is evidence that protein kinase C is involved in the pathway of inducer-mediated differentiation (29). The in vitro studies provided a basis for evaluating the potential of HMBA as a cytodifferentiation agent in the treatment of human cancers (30). Several phase I clinical trials with HMBA have been completed (31-36). Clinical trials have shown that this compound can induce a therapeutic response in patients with cancer (35,36). However, these phase I clinical trials also have demonstrated that the potential efficacy of HMBA is limited, in part, by dose-related toxicity which prevents achieving optimal blood levels and by the need for intravenous administration of large quantities of the agent, over prolonged periods.

Recently, the present inventors have reported a number of compounds related to HMBA with polar groups separated by apolar linkages that, on a molar basis, are as active (37) or 100 times more active than HMBA (38). As a class, however, it has been found that the symmetrical dimers such as HMBA and related compounds are not the best cytodifferentiating agents.

It has unexpectedly been found that the best compounds comprise two polar end groups separated by a flexible chain of methylene groups, wherein one or both of the polar end groups is a large hydrophobic group. Preferably, the polar end groups are different and only one is a large hydrophobic group. These compounds are unexpectedly a thousand time more active than HMBA and ten times more active than HMBA related compounds.

This new class of compounds of the present invention may be useful for selectively inducing terminal differentiation of neoplastic cells and therefore aid in treatment of tumors in patients.

SUMMARY OF THE INVENTION

The present invention provides the compound having the structure:

Figure USRE038506-20040420-C00002

wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.

The present invention also provides the compound above having the structure:

Figure USRE038506-20040420-C00003

wherein each of R3 and R4 are independently the same as or different from each other are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group; R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.

The present invention also provides the compound above having the structure:

Figure USRE038506-20040420-C00004

wherein R is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; and n is an integer from about 4 to about 8.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00005

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; R is a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.

The present invention further provides the compound having the structure:

Figure USRE038506-20040420-C00006

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m, n, and o are independently the same as or different from each other and are each an integer from about 0 to about 8.

The present invention still further provides the compound having the structure:

Figure USRE038506-20040420-C00007

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to 8.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00008

wherein each of X and Y are independently, the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.

The present invention also provides the compound having the structure

Figure USRE038506-20040420-C00009

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to 8.

The present invention further provides the compound having the structure:

Figure USRE038506-20040420-C00010

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and n is an integer from about 0 to about 8.

The present invention still further provides the compound having the structure:

Figure USRE038506-20040420-C00011

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, aryloxy, carbonylhydroxylamino, or fluoro group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00012

wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00013

wherein each of R1 and R2 are independently the same as or different form each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.

The present invention further provides the compound having the structure:

Figure USRE038506-20040420-C00014

wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.

In addition, the present invention provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation.

The present invention also provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.

Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of any of the compounds above.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides the compound having the structure:

Figure USRE038506-20040420-C00015

wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridino group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.

The present invention also provides the compound above having the structure:

Figure USRE038506-20040420-C00016

wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group; R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.

In the preferred embodiment of the compound above, R2 is a hydroxylamino, hydroxyl, amino, methylamino, dimethylamino, or methoxy group and n is 6. Most preferably, R4 is a hydrogen atom and R3 is a substituted or unsubstituted phenyl group.

The phenyl group may be substituted with a methyl, cyano, nitro, trifluoromethyl, amino, aminocarbonyl, methylcyano, chloro, fluoro, bromo, iodo, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 3,5-difluoro, 2,6-difluoro, 1,2,3-trifluoro, 2,3,6-trifluoro, 2,4,6-trifluoro, 3,4,5-trifluoro, 2,3,5,6-tetrafluoro, 2,3,4,5,6-pentafluoro, azido, hexyl, t-butyl, phenyl, carboxyl, hydroxyl, methyoxy, benzyloxy, phenylaminooxy, phenylmethoxy, phenylaminocarbonyl, methoxycarbonyl, methylaminocarbonyl, dimethylamino, dimethylaminocarbonyl, or hydroxylaminocarbonyl group.

In other preferred embodiments of the compound above, R4 is a hydrogen atom and R3 is a cyclohexyl group; R4 is a hydrogen atom and R3 is a methyoxy group; R3 and R4 each bond together to form a piperidine group; R4 is a hydrogen atom and R3 is a hydroxyl group; R4 is a hydrogen atom and R3 is a benzyloxy group; R4 is a hydrogen atom and R3 is a δ-pyridine group; R4 is a hydrogen atom and R3 is a β-pyridine group; R4 is a hydrogen atom and R3 is a α-pyridine group; R3 and R4 are both methyl groups; or R4 is a methyl group and R3 is a phenyl group.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00017

wherein R is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; and n is an integer from about 4 to about 8.

In the preferred embodiment of the compound above, R is a substituted or unsubstituted phenylamino group. The phenylamino group may be substituted with a cyano, methylcyano, nitro, carboxyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, trifluoromethyl, hydroxylaminocarbonyl, N-hydroxylaminocarbonyl, methoxycarbonyl, chloro, fluoro, methyl, methoxy, 2,3-difluoro, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 2,6-difluoro, 3,5-difluoro, 2,6-difluoro, 2,3,6-trifluoro, 1,2,3-trifluoro, 3,4,5-trifluoro, 2,3,4,5-tetrafluoro, or 2,3,4,5,6-pentafluoro group.

In another embodiment of the compound above, R is a cyclohexylamino group.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00018

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; R is a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy-group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.

In the preferred embodiment of the compound above, each of X, Y, and R is a hydroxyl group and each of m and n is 5.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00019

wherein each of X and Y are independently the same as or different form each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m, n, and o are independently the same as or different from each other and are each an integer from about 0 to about 8.

In the preferred embodiment of the compound above, each of X and Y is a hydroxyl group and each of R1 and R2 is a methyl group. Most preferably, each of n and o is 6, and m is 2.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00020

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00021

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.

In the preferred embodiment of the compound above, each of X and Y is a hydroxyl group and each of m and n is 5.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00022

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00023

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and n is an integer from about 0 to about 8.

In the preferred embodiment of the compound above, each of X and Y is a dimethylamino group and n is 4 or 5.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00024

wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, aryloxy, carbonylhydroxylamino, or fluoro group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.

In the preferred embodiment of the compound above, each of X and Y is a hydroxylamino group, R1 is a methyl group, R2 is a hydrogen atom, and each of m and n is 2. In another preferred embodiment, each of X and Y is a hydroxylamino group, R1 is a carbonylhydroxylamino group, R2 is a hydrogen atom, and each of m and n is 5. In a further preferred embodiment, each of X and Y is a hydroxylamino group, each of R1 and R2 is a fluoro group, and each of m and n is 2.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00025

wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.

Preferably, R1 is a phenylamino group and R2 is a hydroxylamino group.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00026

wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.

Preferably, R1 is phenylamino group and R2 is hydroxylamino group.

The present invention also provides the compound having the structure:

Figure USRE038506-20040420-C00027

wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.

In the preferred embodiment, either R1 or R2 is a hydroxylamino group.

The present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation.

The contacting must be performed continuously for a prolonged period of time, i.e. for at least 48 hours, preferably for about 4-5 days or longer.

The method may be practiced in vivo or in vitro. If the method is practiced in vitro, contacting may be effected by incubating the cells with the compound. The concentration of the compound in contact with the cells should be from about 1 μM to about 25 mM, preferably from 4 μM to about 5 mM. The concentration depends upon the individual compound and the state of the neoplastic cells.

The method may also comprise initially treating the cells with an antitumor agent so as to render them resistant to an antitumor agent and subsequently contacting the resulting resistant cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such cells.

The antitumor agent may be one of numerous chemotherapy agents such as an alkylating agent, an antimetabolite, a hormonal agent, an antibiotic, colchicine, a vinca alkaloid, L-asparaginase, procarbazine, hydroxyurea, mitotane, nitrosoureas or an imidazole carboxamide. Suitable agents are those agents which promote depolarization of tubulin. Preferably the antitumor agent is colchicine or a vinca alkaloid; especially preferred are vinblastine and vincristine. In embodiments where the antitumor agent is vincristine, the cells preferably are treated so that they are resistant to vincristine at a concentration of about 5 mg/ml. The treating of the cells to render them resistant to an antitumor agent may be effected by contacting the cells with the agent for a period of at least 3-5 days. The contacting of the resulting cells with any of the compounds above is performed as described previously.

The present invention also provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.

The method of the present invention is intended for the treatment of human patients with tumors. However, it is also likely that the method would be effective in the treatment of tumors in other mammals. The term tumor is intended to include any cancer caused by the proliferation of neoplastic cells, such as lung cancer, acute lymphoid myeloma, bladder melanoma, renal carcinoma, breast carcinoma, or colorectal carcinoma. The administration of the compound to the patient may be effected orally or parenterally. To date administration intravenously has proven to be effective. The administration of the compound must be performed continuously for a prolonged period of time, such as for at least 3 days and preferably more than 5 days. In the most preferred embodiments, the administration is effected continuously for at least 10 days and is repeated at intervals wherein at each interval the administration is continuously effected for at least 10 days. For example, the administration may be effected at intervals as short as 5-10 days, up to about 25-35 days and continuously for at least 10 days during each such interval. The optimal interval period will vary depending on the type of patient and tumor. For example, in the incidence of acute leukemia, the so called myelodysplastic syndrome, continuous infusion would seem to be indicated so long as the patient tolerated the drug without toxicity and there was a positive response.

The amount of the compound administered to the patient is less than an amount which would cause toxicity in the patient. In the certain embodiments, the amount of the compound which is administered to the patient is less than the amount which causes a concentration of the compound in the patient's plasma to equal or exceed the toxic level of the compound. Preferably, the concentration of the compound in the patient's plasma is maintained at about 1.0 mM. It has been found with HMBA that administration of the compound in an amount from about 5 gm/m2/day to about 30 gm/m2/day, particularly about 20 gm/m2/day, is effective without producing toxicity in the patient. The optimal amount of the compound which should be administered to the patient in the practice of the present invention will depend on the particular compound used and the type of cancer being treated.

This invention, in addition to the above listed compounds, is intended to encompass the use of homologs and analogs of such compounds. In this context, homologs are molecules having substantial structural similarities to the above-descried compounds and analogs are molecules having substantial biological similarities regardless of structural similarities.

The method may also comprise initially administering to the patient an amount of an antitumor agent to render the cells resistant to an antitumor agent and subsequently administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.

The antitumor agent may be one of numerous chemotherapy agents such as an alkylating agent, an antimetabolite, a hormonal agent, an antibiotic, colchicine, a vinca alkaloid, L-asparaginase, procarbazine, hydroxyurea, mitotane, nitrosoureas of an imidazole carboxamide. Suitable agents are those agents which promote depolarization of tubulin. Preferably the antitumor agent is colchicine or a vinca alkaloid; especially preferred are vinblastine and vincristine. In embodiments where the antitumor agent is vincristine, an amount is administered to render the cells are resistant to vincristine at a concentration of bout 5 mg/ml. The administration of the agent is performed essentially as described above for the administration of any of the compounds. Preferably, the administration of the agent is for a period of at least 3-5 days. The administration of any of the compounds above is performed as descried previously.

The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier, such as sterile pyrogen-free water, and a therapeutically acceptable amount of any of the compounds above. Preferably, the effective amount is an amount effective to selectively induce terminal differentiation of suitable neoplastic cells and less than an amount which causes toxicity in a patient.

Lastly, the present invention provides the pharmaceutical composition above in combination with an antitumor agent. The antitumor agent may be any of the agents previously described.

The invention is illustrated in the Experimental Details section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be construed to, limit in any way the invention as set forth in the claims, which follow thereafter.

EXPERIMENTAL DETAILS Cells and Materials

MELC 745A-DS19 cells and the variants of MELC derived from this cell line, namely, the vincristine-resistant MELC V3.17 and VCR.C(2)15 cell lines (26), and the dimethylsulfoxide-resistant cell line, DR10 (39), were maintained in alpha minimal essential medium containing 10% fetal calf serum (16). Cell cultures for all experiments were initiated with cells in logarithmic growth phase (day 2 cultured cells) at a density of 105 cells/ml. Inducer compounds were added in the final concentrations indicated below, dissolved in culture medium without fetal calf serum unless otherwise indicated. Cell density and benzidine reactively were determined as described (16).

Commitment to terminal differentiation, characterized by limited cell division (colony size<32 cells) and accumulation of hemoglobin (benzidine reactive colonies) was assayed by a colony cloning assay using 2% methylcellulose as described (25) (see Table 1 for results). HL-60 human leukemia cells, derived from peripheral blood leukocytes of a patient with acute promyelocytic leukemia (40). Induced differentiation of HL-60 cells assayed by determining the proportion of cells that developed the capacity to reduce nitroblue tetrazolium (NBT) (41) (see Table 2 for results).

Chemistry

The compounds having the structure:

Figure USRE038506-20040420-C00028

Preparation of PhCH2ONHOC(CH2)6COOCH3:

A solution of suberic acid monomethyl ester (1.9 g; 0.01 mol), oxaloyl chloride (1.75 mL; 2.54 g; 0.02 mol) and 0.1 mL DMF in benzene (200 mL) was stirred overnight at room temperature. The solvent was evaporated and oily residue was dissolved in chloroform (˜20 mL) and mixed together with chloroform solution (100 mL) of O-benzylhydroxylamine (2.46 g; 0.02 mol) and pyridine (1.6 mL; 1.68 g; 0.02 mol). The reaction mixture was stirred at room temperature overnight. The chloroform solution was washed with water (50 mL), 10% hydrochloric acid, and again with water (2×50 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was slurried in hexanes (˜100 mL) and filtered. The yield of PhCH2ONHOC(CH2)6COOCH3 was 2.61 g (89%).

Figure USRE038506-20040420-C00029

The above suberic acid monobenzyloxyamide monomethyl ester (1 g; 3.4 mol) was dissolved in dry methanol (50 mL) and 5% Pd-C (50 mg) was added. The black suspension was shaken under hydrogen pressure (˜50 psi) overnight at room temperature. The catalyst was separated by filtration, and filtrate was evaporated. The solid residue was slurried in hexanes (˜20 mL) and filtered. The yield of the monomethyl ester monohydroxamic acid of suberic acid was 900 mg (95%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 8.89 (s, broad, NHOH, 1H); 3.57 (s, CH3, 3H); 2.27 (t, J=7.4 Hz, CH2COOCH3, 2H); 1.91 (t, J=7.4 Hz, CH2CONHOH, 2H); 1.49 (m, 4H), 1.24(m, 4H).

Figure USRE038506-20040420-C00030

Suberic acid monobenzyloxyamide monomethyl ester (1 g; 3.4 mmol) and potassium hydroxide (210 mg; 3.75 mmol) were dissolved in 10 mL of methanol-water (4:1) mixture. The reaction mixture was refluxed two hours and solvent was evaporated. The solid residue was dissolved in 5 mL water and acidified with conc. hydrochloric acid to pH˜5. White precipitate was filtered, dried and crystallized from ethyl acetate-hexanes. The yield of suberic acid monobenzyloxyamide was 820 mg (86%). The product was dissolved in methanol (50 mL) and 5% Pd-C (50 mg) was added. The reaction mixture was shaken under hydrogen pressure (50 psi) overnight. The catalyst was separated by filtration and filtrate was evaporated. The solid residue was slurried in hexanes and filtered. The yield of suberic acid monohydroxamic acid was 520 mg (81%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.96 (s, broad, COOH, 1H); 10.31 (s, NHOH, 1H); 8.63 (s, broad NHOH, 1H); 2.17 (s, J=7.4 Hz, CH2COOH, 2H); 1.91 (s, CH2CONHOH, 2H); 1.46 (m, 4H); 1.22 (m, 4H).

Compounds having the structure:

Figure USRE038506-20040420-C00031

General Procedure

A pyridine (500 mL) solution of O-benzylhydroxylamine (2.46 g; 0.02 mol), the corresponding amine (0.02 mol) and suberoyl chloride was stirred at room temperature overnight. The solvent was evaporated and the semisolid residue was dissolved in 100 mL chloroform-methanol (4:1); the resulting solution was washed with water (2×100 mL), 10% hydrochloric acid (3×100 L), and again with water (2×100 mL). Organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was dissolved in methanol (100 mL) and 5% Pd-C was added. The black suspension was shaken under hydrogen pressure (˜50 psi) overnight. The catalyst was separated by filtration, and the filtrate was evaporated. The target products were isolated by column chromatography on silica gel with ethyl acetate-tetrahydrofuran.

Figure USRE038506-20040420-C00032

Yield 1.1 g (26%). 1H NMR (DMSO-D2, 200 MHz), δ(ppm) 10.93 (s, NHOCH3, 1H); 10.32 (s, NHOH, 1H); 8.66 (s, NHOH, 1H); 3.55 (s, CH3, 3H); 1.19 (t, J=7.6 Hz, CH2CO—,4H); 1.45 (m, 4H); 1.20 (m, 4H).

Figure USRE038506-20040420-C00033

Yield 1.2 g (21%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 8.60 (s, broad, NHOH, 1H); 7.57 (d, J=7.6 Hz, NH—C6H11, 1 H), 3.40 (m, CH—NH, 1H); 1.99 (t, J=7Hz, CH2CONHC6H11, 2H; 1.91 (t, J=7.6 Hz, CH2CONHOH, 2H); 2.63 (m, 4H); 1.44 (m, 6H); 1.20 (m, 8H).

Figure USRE038506-20040420-C00034

Yield 870 mg (20%); 1H NMR (DMSO-D6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 8.67 (s, broad, NHOH, 1H); 2.85 (d, J=30 Hz, N(CH3)2, 6H); 2.24 (t, J=7.4 Hz, CH2CON(CH3), 2H); 1.91 (t, J=7.4 Hz, CH2COONHOH, 2H); 1.50 (m, 4H); 1.20 (m, 4H).

Figure USRE038506-20040420-C00035

Yield 1.4 g (27%) 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 8.67 (s, NHOH, 1H); 3.40 (2t, CH2N, 4H); 2.20 (t, J=7.4 Hz, CH2CON(CH2)5, 2H); 1.91 (t, J=7.4 Hz, CH2CONHOH, 2H); 1.10-1.60 (m, broad, 14H).

Compound having structure:

Figure USRE038506-20040420-C00036

The chloroform (500 mL) solution of O-benzylhydroxylamine (1.23 g; 0.01 mol), O-(trimethylsilyl)hydroxylamine (1.1 g; 0.01 mol), pyridine (1.6 mL; 1.7 g; 0.02 mol) and suberoyl chloride (1.8 mL; 2.11 g; 0.01 mol) was stirred at room temperature overnight. The reaction suspension was diluted with methanol (100 mL), washed with 10% hydrochloric acid (3×100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was subjected to chromatography on silica gel in ethyl acetate-tetrahydrofuran (4:1). The yield was 500 mg (17%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.09 (s, NHOCH2C6H5, 1H); 10.31 (s, NHOH, 1H); 8.67 (s, broad, NHOH, 1H); 7.36 (s, C6H5, 5H), 4.76 (s, CH2C6H5, 2H); 1.92 (t, J=7.4 Hz, CH2CO—, 4H); 1.45 (m, 4H); 1.20 (m, 4H).

Compound having the structure:

Figure USRE038506-20040420-C00037

Into a cooled solution of potassium hydroxide (2.24 g; 0.04 mol) and O-benzylhydroxylamine hydrochloride in 30 mL of tetrahydrofuran-water (1:1) mixture, 6-bromohexanoyl chloride (3.1 mL; 4.27 g; 0.02 mol) was added. The reaction mixture was stirred at room temperature for one hour. The solvent was evaporated and solid residue was partitioned between chloroform (200 mL) and water (100 mL). Chloroform layer was washed with 10% hydrochloric acid (3×50 mL) and water (2×50 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The product was purified by crystallization from ethyl acetate-hexanes. The yield of N-benzyloxy-6-bromohexanoyl amide was 4.7 g (78%). A dimethylsulfoxide (250 mL) solution of N-benzyloxy-6-bromohexanoyl amide (4.5 g; 15 mmol) and sodium cyanide (7.35 g; 0.15 mol) was heated at 130° C. overnight. The solvent was evaporated and solid residue was partitioned between chloroform (300 mL) and water (300 mL). The chloroform layer was washed with water (5×100 mL), dried over anhydrous magnesium sulfate, and evaporated. The oily residue was purified by column chromatography on silica gel in ethyl acetate-tetrahydrofuran (4:1) as an eluent. The yield of N-benzyloxy-6-cyanohexanoylamide was 1.62 g (43%). The product was dissolved in methanol (50 mL) and 5% Pd-C (100 mg) was added. The black suspension was shaken under hydrogen pressure (˜50 psi) overnight. The catalyst was isolated by filtration and filtrate was evaporated. The solid residue was slurried in hexanes (˜20 mL) and filtered. The yield of N-hydroxy-6-cyanohexanoylamide was 900 mg (overall yield 30%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.32 (s, NHOH, 1H); 8.65 (s, NHOH, 1H); 2.45 (t,J=7 Hz, CH2CN, 2H) 1.93 (t, J=7 Hz, CH2CONHOH, 2H); 1.49 (m, 4H); 1.33 (m, 2H).

Compounds having the structure:

Figure USRE038506-20040420-C00038

General Procedure

A diacid dichloride (0.01 mol) was added into a cooled (0° C.) solution of potassium hydroxide (1.12 g: 0.02 mol) and corresponding amine (0.01 mol) in 30 mL of tetrahydrofuran-water (1:1) mixture. The reaction mixture was stirred at room temperature about one hour. Solvent was evaporated and the solid residue was partitioned between chloroform (300 mL) and water (300 mL). In some cases a small amount of methanol is necessary to dissolve all solid. The organic layer was washed with 10% potassium hydroxide (3×30 mL). The basic water extract was acidified with 10% hydrochloric acid. The precipitate was collected by filtration, dried and purified by crystallization from ethyl acetate or by column chromatography on silica gel in ethyl acetate-tetrahydrofuran (4:1). The yields are from 20-37%.

Figure USRE038506-20040420-C00039

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.97 (s, COOH, 1H); 9.84 (s, NH, 1H); 7.57 (d, J=7.4 Hz, ortho aromatic protons, 2H); 7.26 (t, J=8.4 Hz, meta aromatic protons 2H); 6.99 (t, J=7.4 Hz, para aromatic proton, 1H), 2.27 (t, J=7 Hz, CH2CONHPh, 2H); 2.18 (t, J=7.2 Hz, 2H); 1.52 (m, 4H); 1.28 (m, 4H).

Figure USRE038506-20040420-C00040

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.95 (s, COOH, 1H); 10.20 (s, NH, 1H); 8.10 (s, aromatic proton, 1H); 7.75 (m, aromatic proton, 1H); 7.45 (m, aromatic proton, 2H); 2.28 (t, J=7.4 Hz, CH2CONHAr, 2H); 2.21 (t, J=7.2 Hz, CH2COOH, 2H); 1.46 (m, 4H); 1.20 (m, 4H).

Figure USRE038506-20040420-C00041

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.95 (s, COOH, 1H); 10.29 (s, NH, 1H); 7.75 (s, aromatic protons, 4H); 2.33 (t, J=7.2 Hz, CH2CONHAr, 2H); 2.18 (t, J=7.4 Hz, CH2COOH, 2H); 1.53 (m, 4H); 1.27 (m, 4H).

Figure USRE038506-20040420-C00042

1H NMR (DMSO-D6, 200 MHz), 11.98 (s, broad, COOH, 1H); 10.48 (s, NH, 1H); 8.21 (d, J=9.2 Hz, aromatic protons, 2H); 7.82 (d, J=9.2 Hz, aromatic proton 2H); 2.36 (t, J=7.4 Hz, CH2CONHAr, 2H); 2.18 (t, J=7.2 Hz, CH2COOH, 2H); 1.55 (m, 4H); 1.29 (m, 4H).

Figure USRE038506-20040420-C00043

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 12.00 (s, broad COOH, 2H); 10.24 (s, NH, 1H); 8.38 (d, J=5.8 Hz, aromatic protons, 2H); 7.55 (d, J=5.8 Hz, aromatic protons, 2H); 2.33 (t, J=7.2 Hz, CH2CONHAr, 2H); 2.18 (t, J=7.2 Hz, CH2COOH); 1.52 (m, 4H); 1.27 (m, 4H).

Figure USRE038506-20040420-C00044

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.95 (s, COOH, 1H); 7.58 (d, J=8 Hz); 3.50 (m, CH, 1H); 2.17 (t, J=7.2 Hz, CH2COOH, 2H); 2.00 (t, J=7 Hz, CH2CONH—, 2H); 1.60 (m, 4H); 1.46 (m, 6H); 1.20 (m, 8H).

In the same way the following compounds were prepared and characterized:

Figure USRE038506-20040420-C00045

wherein N=4, 5, 6, 7, and 8; R is hydrogen; 2-, 3-, and 4-cyano; 2-, 3-, and 4-nitro; 2-, 3-, and 4-methylcyano; 2-, 3-, and 4-trifluoromethyl; 2-, 3-, and 4-fluoro:

Figure USRE038506-20040420-C00046

wherein n=4, 5, 6, 7, and 8:

Figure USRE038506-20040420-C00047

wherein n=4, 5, 6, 7, and 8;

Figure USRE038506-20040420-C00048

wherein n=4, 5, 6, 7, and 8;

Figure USRE038506-20040420-C00049

wherein n=4, 5, 6, 7, and 8;

Figure USRE038506-20040420-C00050

wherein n=4, 5, 6, 7, and 8;

Figure USRE038506-20040420-C00051

wherein R is 2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbonyl; 2-, 3-, and 4-methylaminocarbonyl; 2-, 3-, and 4-dimethylaminocarbonyl; 2-, and 3-, and 4-chloro; 2-, 3-, and 4-bromo; 2-, 3-, and 4- iodo; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2-, 3-, and 4-hydroxyl; 2-, 3-, and 4-amino; and 2-, 3-, and 4-dimethylamino.

Compounds having the general structure:

Figure USRE038506-20040420-C00052

wherein n=4, 5, 6, and 7.

General Procedure A

A pyridine (500 mL) suspension of O-benzylhydroxylamine hydrochloride (3.2 g; 0.02 mol) and the corresponding diacid dichloride (0.04 mol) was stirred at room temperature for three days. Water (10 mL) was added and stirring was continued overnight. The solvent was evaporated and solid residue was purified by column chromatography on silica gel in tetrahydrofuran-methanol. The diacid produce was dissolved in methanol (100 mL) and 5% Pd-C (100 mg) was added. The reaction suspension was shaken overnight under hydrogen pressure (˜50 psi). The catalyst was separated by filtration, solid residue was washed with hot methanol (5×50 ml). The combined methanolic filtrates were evaporated. The solid residue was slurried in acetone and filtered. The yield was 10-20%.

General procedure B

A pyridine (500 ml) solution of O-benzylhydroxylamine (2.46 g; 0.02 mol) and the corresponding dicarboxylic acid monobenzyl ester monoacid chloride (0.04 mol) was stirred at room temperature overnight. The solvent was evaporated. The semisolid residue was dissolved in chloroform (300 mL) and extracted with 5% hydrochloric acid (2×50 mL), 10% potassium hydroxide (3×100 mL), and water (2×100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was purified by column chromatography on silica gel in ethyl acetate. The tribenzyl product was dissolved in methanol (100 mL) and 5% Pd-C (100 mg) was added. The reaction suspension was shaken under hydrogen pressure (˜50 psi) at room temperature overnight. The solid was separated by filtration and washed with hot methanol (5×50 mL). The combined methanol filtrates were evaporated to solid residue. The solid residue was slurried in cooled acetone and filtered. The yield of target product was 30-60%.

Figure USRE038506-20040420-C00053

1H NMR (DMSO-d6, 200MHz), δ(ppm) 11.53 (s, COOH, 1H); 2.41 (t, J=7.2 Hz, CH2CON(OH)COCH2, 4H); 2.18 (t, J=7.0 Hz, CH2COOH, 4H); 1.52 (m, 8 h); 1.22 (m, H). MS (FAB, glycerin) 346(M+1)

Compounds having the structure:

Figure USRE038506-20040420-C00054

A pyridine (500 mL) solution of the monomethyl ester monoacid chloride of dicarboxylic acid (0.02 mol) and N,N′-dimethyl-1, x-diaminoalkane (0.01 mol) was stirred at room temperature overnight. Solvent was evaporated and oily residue was dissolved in chloroform (300 mL). Chloroform solution was washed with water (3×50 mL), 10% potassium hydroxide (3×50 mL), 10% hydrochloric acid (3×50 mL), and again with water (3×50 mL). The organic layer was dried and evaporated. The oily residue was dissolved in potassium hydroxide (1.2 g; 0.021 mol) in 80% methanol (100 mL). The reaction mixture was refluxed two hours. The solvent was evaporated and solid residue was dissolved in water (50 mL) and extracted with chloroform (3×50 mL). Water solution was acidified to pH˜5 and concentrated (to volume of about 10 mL). The water solution or suspension was cooled down and precipitate was separated by filtration. The solid product was purified by crystallization from ethyl acetate. The yield was 40-60%.

Figure USRE038506-20040420-C00055

1H NMR (CDCl2, 200 MHz), δ(ppm) 8.15 (s, broad, COOH, 2H); 3.52+3.45 (2s, CH2N, 4H); 3.01+2.93 (2s, CH3N, 6H); 2.30 (4t, CH2CO, 8H); 1.60 (m, 8H); 1.32 (m, 8H). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 3.44+3.336+3.36 (3s, CH2N, 4H); 2.94+2.90+2.79 (3s, CH2N, 6H); 2.27+2.23 +2.12 (3t, CH2CO, 8H); 1.46 (m, 8H); 1.23 (m, 8H).

Compounds having the structure:

Figure USRE038506-20040420-C00056

A pyridine (500 mL) solution of 6-aminocapric acid (2.6 g; 0.02 mol) and terephthaloyl chloride (2g; 0.01 mol) was stirred at room temperature overnight (˜12 hours), and at 90° C. for 23 hours. The solvent was evaporated, and the solid residue was crystallized from water (10 mL) four times. The yield was 800 mg (19%). 1H NMR (DMSO-d6, 200 MH), δ(ppm) 12.8 (s, broad, COOH, 2H); 8.54+7.72 (2t, NH, 2H); 3.24+2.98 (2m, NHCH2, 4H); 220+2.03 (2m, CH2CO, 4H); 1.50 (m, 8H); 1.32 (m, 4H).

Compound having the structure:

Figure USRE038506-20040420-C00057

Into a mixture of aniline (2.75 g; 0.03 mol), hydroxy-lamine hydrochloride (2.08 g; 0.03 mol), and potassium hydroxide (5.50 g; 0.09 mol) in 50% tetrahydrofuran (100 mL) was slowly added at room temperature a tetrahydrofuran (20 mL) solution of terephthaloyl chloride (6g; 0.03 mol). The reaction suspension was stirred at room temperature for thirty minutes. The solvent was evaporated. The solid residue was slurried in hot methanol (1000 mL) and dried over anhydrous magnesium sulfate. The methanol solution was separated by filtration and filtrate was evaporated. The solid residue was slurried in 20 mL cooled methanol and filtered. The white crystals were washed with ether (5×50 mL) and dried. The yield was 4.6 g (39%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.35 (s, broad, NHOH, 1H); 10.35 (s, NHPh, 1H); 9.19 (s, NHOH, 1H); 8.03 (d, J=8 Hz, terephthalic protons, 2H); 7.89 (d, J=8 Hz, terephthalic protons, 2H); 7.82 (d, J=7.4 Hz, ortho anilide protons, 2H); 7.34 (t, =7.4 Hz, meta anilide protons, 2H); 7.10 (t, J=7.4 Hz, para anilide proton, 1H).

Compound having the structure:

Figure USRE038506-20040420-C00058

A solution of 1,4-phenylenediacrylic acid (2.18 g; 0.01 mol) in thionyl chloride (50 mL; 8.55 g; 0.68 mol) was refluxed overnight. The excess of thionyl chloride was evaporated. The solid was dissolved in tetrahydrofuran (20 mL), and added to a cooled (0° C.) solution of potassium hydroxide (1.12 g; 0.02 mol) and aniline in 50% tetrahydrofuran. The reaction mixture was stirred at room temperature for thirty minutes. The solvent was evaporated. The solid residue was slurried in water and filtered. White crystals were dissolved in a small amount of methanol and purified on a silica gel column in tetrahydrofuran. The yield was 315 mg (10%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.80 (s, NHOH, 1H); 10.23 (s, NHPh, 1H); 9.09 (s, NHOH, 1H); 7.69 (d, J=7.6 Hz, ortho anilide protons, 2H); 7.64 (s, phenylene protons, 4H), 7.55 (d, J=15.8 Hz, PhNHOCCH═CH—, 1H); 7.40 (d, J=15.8 Hz, HONHOCCH═CH—, 1H); 7.33 (t, J=7.8 Hz, meta anilide protons, 2H); 7.06 (t, J=7.2 Hz, para anilide protons, 1H); 6.89 (d, J=15.8 Hz, PhNHOCCH═CH—, 1H) 6.51 (d, J=15.8 Hz, HOHNOCCH═CH—, 1H).

Compounds having the structure:

Figure USRE038506-20040420-C00059

wherein n=4, 5, 6, 7, and 8.

A chloroform solution of triethylamine (1.4 mL; 1.0 g; 0.01 mol), the corresponding amine (0.01 mol) and diacid dichloride (0.005 mol) was stirred at room temperature for five hours. If the reaction mixture was clear, it was washed with water (5×100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated to a solid residue. If in the course of reaction a precipitate was formed, the precipitate was separated by filtration. White crystals from filtration or solid residue from evaporation were crystallized from ethyl acetate, tetrahydrofuran, methanol, or their mixture. The yields were from 60-90%.

Figure USRE038506-20040420-C00060

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.23 (s, NH, 2H); 7.82 (d, J=9 Hz, aromatic protons, 4H), 7.60 (d, J=9 Hz, aromatic protons, 4H), 2.31 (t, J=7.4 Hz, CH2CO, 4H); 2.61 (m, 4H); 1.32 (m, 4H),

Figure USRE038506-20040420-C00061

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.48 (s, NH, 2H); 8.18 (d, J=9.2 Hz, aromatic protons, 4H); 7.81 (d, J=9.2 Hz, aromatic protons, 4H0; 2.37 (t, J=7.2 Hz, CH2CO—, 4H); 1.60 (m, 4H); 1.33 (m, 4H),

Figure USRE038506-20040420-C00062

1H NMR (DMSO-d6200 MHz), δ9.91 (s, NH, 2H), 7.58 (d, J=8.6 Hz, aromatic protons, 4H); 7.26 (d, J=8.6 Hz, aromatic protons, 4H); 3.94 (s, CH2CN, 4H); 2.29 (t, J=7.4 Hz, CH2CO—, 4H); 1.60 (m, 4H); 1.31 (m, 4H).

Figure USRE038506-20040420-C00063

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.08 (s, CONHAr, 2H); 7.79 (d, J=8.6 Hz, aromatic protons, 4H); 7.63 (d, J=8 Hz, aromatic protons, 4H), 7.22 (s, H3CHNCO—, 2H); 3.32 (s, CH3, 6H); 2.31 (t, J=7 Hz, CH2C—), 6H); 1.59 (m, 4H); 1.31 (m, 4H).

Figure USRE038506-20040420-C00064

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.90 (s, broad, NHOH, 2H); 10.05 (s, NHAr, 2H); 8.90 (s, broad, NHOH, 2H); 7.68 (d, J=9 Hz, aromatic protons, 4H); 7.62 (d, J=9 Hz, aromatic protons, 4H); 2.31 (t, J=7.2 Hz, CH2CO—, 4H); 1.59 (m, 4H); 1.30 (m, 4H).

Figure USRE038506-20040420-C00065

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.06 (s, broad, NH, 2H); 8.71 (d, J=2.6 Hz, aromatic protons, 2H); 7.31 (d+d, aromatic protons, 2H); 2.32 (t, J=7.4 Hz, CH2CO—, 4H); 1.59 (m, 4H); 1.33 (m, 4H).

Figure USRE038506-20040420-C00066

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 12.00 (s, broad, NH, 2H); 7.43 (d, J=3.6 Hz, aromatic protons, 2H); 7.16 (d, J=3.6 Hz, aromatic protons 2H); 2.41 (t, J=7.2 Hz, CH2CONH—, 4H) 1.58 (m, 4H); 1.28 (m, 4H).

In the similar manner, the following compounds were prepared and characterized:

Figure USRE038506-20040420-C00067

wherein n=4, 5, 6, 7, and 8; all compounds are symmetrical wherein R is 2-, 3-, and 4-cyano; 2-, 3-, and 4-methylcyano; 2-, 3-, and 4-nitro, 2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbonyl; 2-, 3-, and 4-methylaminocarbonyl; 2-, 3-, and 4-dimethylaminocarbonyl; and 2-, 3-, and 4-trifluoromethyl;

Figure USRE038506-20040420-C00068

wherein R is 4-hydroxylaminocarbonyl; 4-methoxycarbonyl; 2-, 3-, and 4-chloro; 2-, 3-, and 4-fluoro; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2,3 -difluoro; 2,4-difluoro; 2,5-difluoro; 2,6-difluoro; 1,2,3,-trifluoro, 3,4,5-trifluoro; 2,3,5,6-tetrafluoro; 2,3,4,5,6-pentafluoro

Figure USRE038506-20040420-C00069

Compounds having the structure:

Figure USRE038506-20040420-C00070

wherein n=4, 5, 6, 7, and 8.

General procedure A

A diacid dichloride (0.01 mol) as added to a stirred solution of potassium hydroxide (1.68 g; 0.03 mol), hydroxylamine hydrochloride (0.7 g; 0.01 mol), and the corresponding aniline (0.01 mol) in 50 % tetrahydrofuran (100 mL). The resulting reaction mixture was stirred at room temperature thirty minutes, and solvent was evaporated to solid residue. The solid residue was slurried in methanol (˜100 mL) and dried over anhydrous magnesium sulfate. The methanol solution was separated by filtration and evaporated to a solid residue. The product was purified by column chromatography on silica gel in ethyl acetate-tetrahydrofuran (in most cases 3:1). The yields were 15-30%.

General procedure B

A solution of corresponding monomethyl ester of dicarboxylic acid (0.01 mol), oxaloyl chloride (0.03 mol), and a few drops DMF in benzene (500 mL) was stirred at room temperature overnight. The solvent was evaporated and the oily residue was dissolved in dry benzene (3×50 mL) and evaporated again. The tetrahydrofuran (50 mL) solution of monoester monoacid chloride of the corresponding dicarboxylic acid was slowly added to a cooled solution of the corresponding amine (0.01 mol) and pyridine (1.6 mL; 1.6 g; 0.02 mol) in tetrahydrofuran (200 mL). The reaction mixture was stirred at room temperature for an hour. The solvent was evaporated, the reside was dissolved in chloroform (300 mL), and the chloroform solution was washed with 10% hydrochloric acid (3×50 mL), 10% potassium hydroxide (3×50 mL), and water (3×50 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated, yielding the pure monoester monoamide of dicarboxylic acid. The product was dissolved in 80% methanol with potassium hydroxide (0.56 g; 0.01 mol). The reaction mixture was refluxed two hours and evaporated to solid residue. The residue was dissolved in water (˜20 mL) and acidified to ˜pH 5 with 10% hydrochloric acid. The monoacid monoamide of the dicarboxylic acid was isolated by filtration of precipitate or extraction water solution with chloroform. The isolated monoacid monoamide of the dicarboxylic acid was mixed together with an equivalent amount of O-benzylhydroxylamine and 1,3-dicyclohexylcarbodiimide in pyridine (˜100 mL per 0.01 mol of O-benzylhydroxylamine) and was stirred at room temperature overnight. The solvent was evaporated and the solid residue was partitioned between chloroform (500 mL) and 10% hydrochloric acid (300 mL). The organic layer was washed with water (3×100 mL) and dried over anhydrous magnesium sulfate. The solvent was evaporated to solid residue. The solid residue was dissolved in large amounts of tetrahydrofuran and filtered through a short column of silica gel. The crude product was dissolved in methanol (100 mL) and 5% Pd-C was added. The reaction suspension was shaken under hydrogen pressure (˜50 psi) overnight. The catalyst was separated by filtration and filtrate was evaporated to solid residue. The solid residue was slurried in hexanes and filtered. Mostly pure product was isolated in this way. If necessary further purification was achieved by column chromatography on silica gel with ethyl acetate-tetrahydrofuran. The yields were from 35% to 65%.

General procedure C

A pyridine (500 mL solution of O-benzylhydroxylamine (1.23; 0.01 mol), the corresponding amine (0.01 mol), and the dichloride of the dicarboxylic acid (0.01 mol) was stirred at room temperature overnight. The solvent was evaporated and the white solid residue contains, judged by 1H NMR, two symmetrical amides and a target unsymmetrical one. The solid residue was slurried in methanol and dried over anhydrous magnesium sulfate. The filtrate was evaporated and the solid residue was dissolved in methanol (˜100 mL). Into the methanol solution 5% Pd-C (100 mg) was added and the black suspension was shaken under hydrogen pressure (˜50 psi) overnight. The catalyst was separated by filtration and the filtrate was evaporated. The product was isolated by column chromatography on silica with ethyl acetate-tetrahydrofuran. The yields were from 20% to 35%.

General procedure D

A chloroform solution of triethylamine (3mL; 2.18 g; 0.0215 mol), the corresponding amine (0.01 mol), O-trimethylsilyl)hydroxylamine (1.05 g, 0.01 mol), and the corresponding diacid chloride of the dicarboxylic acid (0.01 mol) was stirred at room temperature overnight. The solvent was evaporated, the residue was dissolved in methanol (˜10 mL), and into the methanol solution 10% ammonium chloride (˜10 mL) was added. The resulting suspension was stirred at 50° C. for two hours. The solvent was evaporated. The solid residue was slurried in methanol (300 mL) and dried over anhydrous magnesium sulfate. The methanol solution was separated by filtration and evaporated to a solid residue. The product was isolated by silica gel column chromatography with ethyl acetate-tetrahydrofuran. The yields were 20-33%.

Figure USRE038506-20040420-C00071
C H N
Elemental analysis: Calc. 63.62 7.63 10.60
Found 63.58 7.59 10.48

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 9.83 (s, NHPh, 1H); 8.64 (d, NHOH, 2H); 7.57 (d, J=8.2 Hz, ortho aromatic protons, 2H); 7.26 (t, J=8.4 Hz, meta aromatic protons, 2H), 6.99 (t, J=7.4 Hz, para aromatic protons, 1H); 2.27 (t, J=7.4 Hz, CH2CONHPh, 2H); 1.93 (t, J=7.2 Hz, CH2CONHOH, 2H); 1.52 (m, 4H); 1.26 (m, 4H). MS (Fab, Glycerin) 172, 204, 232, 249, 265, (100% M+1).

Figure USRE038506-20040420-C00072

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 10.08 (s, NHPh, 1H); 8.64 (s, NHOH, 1H); 7.78 (d, J=7.6 Hz, aromatic protons, 1H); 7.66 (t, J=7.4 Hz, aromatic protons, 1H); 7.48 (d, J=7.8 Hz, aromatic protons, 1H); 7.29 (t, J=7.4 Hz, aromatic protons, 1H); 2.34 (t, J=7 Hz, CH2CONHAr, 2H); 1.93 (t, J=7.4 Hz, CH2CONHOH, 2H); 1.58 (m, 4H); 1.27 (m, 4H).

Figure USRE038506-20040420-C00073

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 10.21 (s, NHPh, 1H); 8.65 (s, NHOH, 1H); 8.09 (s, aromatic proton, 1H); 7.77 (m, aromatic proton, 1H); 7.49 (m, aromatic proton, 1H); 2.31 (t, J=7.2 Hz, CH2CONHAr, 2H); 1.93 (t, J=7.2 Hz, CH2CONHOH, 2H); 1.51 (m, 4H).

Figure USRE038506-20040420-C00074

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.35 (s, NHAr, 1H); 10.31 (s, NHOH, 1H); 8.63 (s, NHOH-+aromatic proton 2H); 7.88 (d, J=8 Hz, aromatic protons 2H); 7.57 (t, J=8 Hz, aromatic proton, 1H); 2.33 (t, J=7.6 Hz, CH2CONHAr, 2H); 1.93 (t, J=7.4 Hz, CH2CONHOH, 2H), 1.52 (m, 4H); 1.27 (m, 4H),

Figure USRE038506-20040420-C00075

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.33 (s, NHOH, 1H); 10.15 (s, NHAr, 1H); 10.09 (s, NHPh, 1H); 8.66 (s, NHOH, 1H); 7.91 (d, J=8.6 Hz, aromatic protons 2H); 7.76 (d, J=7.8 Hz, ortho aniline protons, 2H); 7.71 (d, J=8.6 Hz, aromatic protons, 2H); 7.33 (t, J=7.6 Hz, meta anilide protons, 2H); 7.07 (t, J=7.4 Hz, para anilide protons); 2.33 (t, J=7.5 Hz, CH2NHAr, 2H); 1.93 (t, J=7.2 Hz, CH2CNHH, 2H); 1.51 (m, 4H); 1.28 (m, 4H).

Figure USRE038506-20040420-C00076

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.32 (s, NHOH, 1H); 10.21 (s, NHAr, 1H); 8.65 (s, NHOH, 1H); 7.31 (d of d, J=10 Hz(2.2 Hz), aromatic protons, 2H); 6.84 (t of t, J=9.4 Hz(2.4Hz), aromatic protons, 1H); 2.29 (t, CH2CONHAr, 2H); 1.93 (t, J=7.2 Hz, CH2CONHOH, 2H); 1.51 (m, 4H); 1.26 (m, 4H).

In the same manner the following compounds were prepared and characterized:

Figure USRE038506-20040420-C00077

wherein n=4, 5, 6, 7, and 8; and R is 2-, 3-, and 4-cyano; 2-, 3-, and 4-methylcyano; 2-, 3-, and 4-nitro; 2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbonyl; 2-, 3-, and 4-methylaminocarbonyl; 2-, 3-, and 4-dimethylaminocarbonyl; and 2-, 3-, and 4-trifluoromethyl;

Figure USRE038506-20040420-C00078

wherein R is 4-hydroxylaminocarbonyl; 4-methoxycarbonyl; 4-tetrazoyl; 2-, 3-, and 4-chloro; 2-, 3-, and 4-fluoro; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2,3-difluoro; 2,4-difluoro; 2,5-difluoro; 2,6-difluoro; 1,2,3-trifluoro; 3,4,5-trifluoro; 2,4,5-trifluoro; 2,4,6-trifluoro; 2,3,6-trifluoro; 2,3,5,6-trifluoro; 2,3,4,5,6-pentafluoro; 2-, 3-, and 4-phenyl; 2-, 3-, and 4-benzyloxy; 4-hexyl; and 4-t-butyl;

Figure USRE038506-20040420-C00079

Compounds having the structure

Figure USRE038506-20040420-C00080

wherein n=4, 5, 6, 7, and 8; and R is hydrogen or methyl.

A diacid dichloride (0.01 mol) was added into a stirred solution of potassium hydroxide (1.68 g; 0.03 mol), aniline or N-methylaniline (0.01 mol), and dimethylamine hydrochloride (0.805 g; 0.01 mol) in 50% tetrahydrofuran (100 mL). The reaction mixture was stirred thirty minutes at room temperature. The solvent was partitioned between chloroform (400 mL) and water (300 mL). The organic layer was washed with 10% hydrochloric acid (3×100 mL), 10% potassium hydroxide (3×100 mL), and water (2×100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was slurried in hexanes and filtered. The yield were 25-34%.

Figure USRE038506-20040420-C00081

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 9.82 (s, NHPh, 1H); 7.58 (d, J=7.6 Hz, ortho aromatic protons, 2H); 7.26 (t, J=7.4 Hz, meta aromatic protons, 2H); 6.99 (t, J=7.4 Hz, para aromatic proton, 1H); 2.85 (d, J=28 Hz, N(CH3)2, 6 H); 2.28 (t, J=7.2 Hz, CH2CO, 2H); 2.24 (t, J=7.4 Hz, CH2CO, 2H); 1.51 (m, 4H); 1.29 (m, 4H).

Figure USRE038506-20040420-C00082

1H NMR (DMSO-d6, 200 MHz), δ(ppm) 7.30 (m, C6H5, 5H); 3.13 (s, H3CNPh, 3H); 2.83 (d, J=26 Hz, N(CH3)2, 6H); 2.17 (t, J=7.6 Hz, CH2CON(CH3)2, 2H); 1.98 (t, J=7.4 Hz, CH2CON(CH3)Ph, 2H); 1.41 (m, 4H); 1.11 (m, 4H).

TABLE 1
Benzidine
Mol. Optimal Reactive
CPD Structure Weight Conc. (μM) Cells (%)
Figure USRE038506-20040420-C00083
1 n = 4 (known compound) 236 80 70
2 n = 5 250 20 84
3 n = 6 264 2.5 70
4 n = 7 278 20 8
5 n = 8 292 20 15
6
Figure USRE038506-20040420-C00084
274 31 44
7
Figure USRE038506-20040420-C00085
274 31 52
8
Figure USRE038506-20040420-C00086
294 12.5 32
9
Figure USRE038506-20040420-C00087
225 50 20
10
Figure USRE038506-20040420-C00088
355 250 26
11
Figure USRE038506-20040420-C00089
216 60 53
12
Figure USRE038506-20040420-C00090
189 250 35
13
Figure USRE038506-20040420-C00091
203 60 17
14
Figure USRE038506-20040420-C00092
156 125 30
15
Figure USRE038506-20040420-C00093
218 20 43
16
Figure USRE038506-20040420-C00094
270 8 35
17
Figure USRE038506-20040420-C00095
256 62 30
18
Figure USRE038506-20040420-C00096
260 31 38
19
Figure USRE038506-20040420-C00097
278 5 24
Figure USRE038506-20040420-C00098
20 R = 4-methyl 273 20 52
21 R = 4-cyano 289 7 70
22 R = 3-cyano 289 5 55
23 R = 2-cyano 289 16 65
24 R = 3-nitro 309 5 30
25 R = 4-nitro 309 0.8 30
26 R = 3-trifluoromethyl 332 30 30
27 R = 4-trifluoromethyl 332 5 47
28 R = 2-amino 279 20 54
29 R = 4-cyanomethyl 303 1 30
30 R = 3-chloro 298.5 2 33
31 R = 4-azido (N3) 304 2 47
32 R = 2-fluoro 282 4 65
33 R = 3-fluoro 282 1 25
34 R = 4-fluoro 282 4 43
35 R = 4-benzyloxy 370 4 20
36 R = 4-methyoxycarbonyl 322 4 28
37 R = 4-methylaminocarbonyl 321 30 16
38 R = 2-bromo 343 8 45
39 R = 2-chloro 298.5 4 34
40 R = 4-bromo 343 1.6 47
41 R = 2,3-difluoro 300 8 24
42 R = 2,4,5-trifluoro 318 8 36
43 R = 2,3,6-trifluoro 318 31 53
44 R = 2,4,6-trifluoro 318 16 47
45 R = 2,4-difluoro 300 6 60
46 R = 2,3,4,5,6-pentafluoro 354 31 53
47 R = 3,4-difluoro 300 4 61
48 R = 3,4,5-trifluoro 318 8 55
49 R = 2,5-difluoro 300 4 70
50 R = 3,5-difluoro 300 2 73
51 R = 2-methoxy 294 8 36
52 R = 3-methoxy 294 6 38
53 R = 4-methoxy 294 6 37
54
Figure USRE038506-20040420-C00099
290 20 40
55
Figure USRE038506-20040420-C00100
256 30 53
Figure USRE038506-20040420-C00101
56 R = tri-fluoromethyl 460 50 20
57 R = 4(N)-hydroxylaminocarbonyl 442 8 10
58 R = 4-cyanomethyl 402 50 25
59 R = 2,4-difluoro 396 500 54
60 R = 2,6-difluoro 396 100 21
61 R = 3,5-difluoro 396 125 31
62 R = 2,3,6-trifluoro 432 250 28
63 R = 2,4,6-trifluoro 432 125 35
64 R = 2,3,4,5,6-pentafluoro 504 125 13
65 R = 4-nitro 414 25 14
66
Figure USRE038506-20040420-C00102
270 1250 80
67
Figure USRE038506-20040420-C00103
256 2500 90
68
Figure USRE038506-20040420-C00104
204 125 56
69
Figure USRE038506-20040420-C00105
333 60 40
70
Figure USRE038506-20040420-C00106
226 160 19
Figure USRE038506-20040420-C00107
71 n = 4 310 100 8
72 n = 5 324 250 10
73 n = 6 338 50 7
74 n = 7 352 100 10
75 n = 8 366 100 10

TABLE 2
Induction of Differentiation of HL-60
Mol. Optimal NBT
CPD Weight Conc. (μM) Positive (%)
2 250 7 22
3 264 1 21
6 274 20 30
7 274 20 21
22 289 1.7 28
21 289 2 6
26 332 6 27
25 309 3 18
36 322 1 32
31 304 2.5 7
29 303 1 15
43 318 2 20

References

1. Sporn, M. B., Roberts, A. B., and Driscoll, J. S. (1985) in Cancer: Principles and Practice of Oncology, eds. Hellman, S., Rosenberg, S. A., and DeVita, V. T., Jr., Ed. 2, (J. B. Lippincott, Philadelphia), P. 49.

2. Breitman, T. R., Selonick, S. E., and Collins, S. J. (1980) Proc. Natl. Acad. Sci. USA 77: 2936-2940.

3. Olsson, I. L. and Breitman, T. R. (1982) Cancer Res. 42: 3924-3927.

4. Schwartz, E. L. and Sartorelli, A. C. (1982) Cancer Res. 42: 2651-2655.

5. Marks, P. A., Sheffery, M., and Rifkind, R. A. (1987) Cancer Res. 47: 659.

6. Sachs, L. (1978) Nature (Lond.) 274: 535.

7. Friend, C., Scher, W., Holland, J. W., and Sato, T. (1971) Proc. Natl. Acad. Sci. (USA) 68: 378-382.

8. Tanaka, M., Levy, J., Terada, M., Breslow, R., Rifkind, R. A., and Marks, P. A. (1975) Proc. Natl. Acad. Sci. (USA) 72: 1003-1006.

9. Reuben, R. C., Wife, R. L., Breslow, R., Rifkind, R. A., and Marks, P. A. (1976) Proc. Natl. Acad. Sci. (USA) 73: 862-866.

10. Abe, E. Miyaura, C., Sakagami, H., Takeda, M., Konno K., Yamazaki, T., Yoshika, S., and Suda, T. (1981) Proc. Natl. Acad, Sci. (USA) 78: 4990-4994.

11. Schwartz, E. L., Snoddy, J. R., Kreutter, D., Rasmussen, H., and Sartorelli, A. C. (1983) Proc. Am. Assoc. Cancer Res. 24: 18.

12. Tanenaga, K., Hozumi, M., and Sakagami, Y. (1980) Cancer Res. 40: 914-919.

13. Lotem, J. and Sachs, L. (1975) Int. J. Cancer 15: 731-740.

14. Metcalf, D. (1985) Science, 229: 16-22.

15. Scher, W., Scher, B. M., and Waxman, S. (1983) Exp. Hematol. 11: 490-498.

16. Scher, W., Scher, B. M., and Waxman, S. (1982) Biochem. & Biophys. Res. Comm. 109: 348-354.

17. Huberman, E. and Callaham, M. F. (1979) Proc. Natl. Acad. Sci. (USA) 76: 1293-1297.

18. Lottem, J. and Sachs, L. (1979) Proc. Natl. Acad. Sci. (USA) 76: 5158-5162.

19. Terada, M., Epner, E., Nudel, U., Salmon, J., Fibach, E., Rifkind, R. A., and Marks, P. A. (1978) Proc. Natl. Acad. Sci. (USA) 75: 2795-2799.

20. Morin, M. J. and Sartorelli, A. C. (1984) Cancer Res. 44: 2807-2812.

21. Schwartz, E. L., Brown, B. J., Nierenberg, M., Marsh, J. C., and Sartorelli, A. C. (1983) Cancer Res. 43: 2725-2730.

22. Sugano, H., Furusawa, M., Kawaguchi, T., and Ikawa, Y. (1973) Bibl. Hematol. 39: 943-954.

23. Ebert, P. S., Wars, I., and Buell, D. N. (1976) Cancer Res. 36: 1809-1813.

24. Hayashi, M., Okabe, J., and Hozumi, M. (1979) Gann 70: 235-238.

25. Fibach, E., Reuben, R. C., Rifkind, R. A., and Marks, P. A. (1977) Cancer Res. 37: 440-444.

26. Melloni, E., Pontremoli, S., Damiani, G., Viotti, P., Weich, N., Rifkind, R. A., and Marks, P. A. (1988) Proc. Natl. Acad. Sci. (USA) 85: 3835-3839.

27. Reuben, R., Khanna, P. L., Gazitt, Y., Breslow, R., Rifkind, R. A., and Marks, P. A. (1978) J. Biol. Chem. 253: 4214-4218.

28. Marks, P. A. and Rifkind, R. A. (1988) International Journal of Cell Cloning 6: 230-240.

29. Melloni, E., Pontremoli, S., Michetti, M., Sacco, O., Cakiroglu, A. G., Jackson, J. F., Rifkind, R. A., and Marks, P. A. (1987) Proc. Natl. Acad. Sciences (USA) 84: 5282-5286.

30. Marks, P. A. and Rifkind, R. A. (1984) Cancer 54: 2766-2769.

31. Egorin, M. J., Sigman, L. M. VanEcho, D. A., Forrest, A., Whitacre, M. Y., and Aisner, J. (1987) Cancer. Res. 47: 617-623.

32. Rowinsky, E. W., Ettinger, D. S., Grochow, L. B., Brundrett, R. B., Cates, A. E., and Donehower, R. C. (1986) J. Clin. Oncol. 4: 1835-1844.

33. Rowinsky, E. L. Ettinger, D. S., McGuire, W. P., Noe, D. A., Grochow, L. B., and Donehower, R. C. (1987) Cancer Res. 47: 5788-5795.

34. Callery, P. S., Egorin, M. J., Geelhaar, L. A., and Nayer, M. S. B. (1986) Cancer Res. 46: 4900-4903.

35. Young, C. W. Fanucchi, M. P., Walsh, T. B., Blatzer, L., Yaldaie, S., Stevens, Y. W., Gordon, C., Tong, W., Rifkind, R. A., and Marks, P. A. (1988) Cancer Res. 48: 7304-7309.

36. Andreeff, M., Young, C., Clarkson, B., Fetten, J., Rifkind, R. A., and Marks, P. A. (1988) Blood 72: 186a.

37. Marks, P. A., Breslow, R., Rifkind, R. A., Ngo, L., and Singh, R. (1989) Proc. Natl. Acad. Sci. (USA) 86: 6358-6362.

38. Breslow, R., Jursic, B., Yan, Z. F., Friedman, E., Leng, L., Ngo, L., Rifkind, R. A., and Marks, P. A. (1991) Proc. Natl. Acad. Sci. (USA) 88: 5542-5546.

39. Ohta, Y., Tanaka, M., Terada, M., Miller, O. J., Bank, A., Marks, P. A., and Rifkind, R. A. (1976) Proc. Natl. Acad. Sci. (USA) 73: 1232-1236.

40. Collins, S. J., Gallo, R. C., and Gallagher, R. E. (1978) Nature (London) 270: 405-409.

41. Synder, S. W., Egorin, M. J., Geelhaar, L. A., Hamburger, A. W., and Callery, P. S. (1988) Cancer Res. 48; 3613-3616.

Claims (24)

What is claimed is:
1. A compound having the structure:
Figure USRE038506-20040420-C00108
wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is and are a substituted or unsubstituted cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiazoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, or alkyloxy group; and n is an integer from about 4 to about 8.
2. A compound of claim 1 having the structure:
Figure USRE038506-20040420-C00109
wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group; R2 is a hydroxylamino, hydroxyl, amino, alkylamino, or alkyloxy group; and n is an integer from about 4 5to about 87; and R3 —N—R 4 and R 2 are different.
3. A compound of claim 2, wherein R2 is a hydroxylamino, hydroxyl, amino, methylamino, or methoxy group and n is 6.
4. A compound of claim 3, wherein R4 is a hydrogen atom and R3 is a substituted or unsubstituted phenyl group.
5. A compound of claim 4, wherein the phenyl group is substituted with a methyl, cyano, nitro, trifluoromethyl, amino, aminocarbonyl, metylcyano, chloro, fluoro, bromo, iodo, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 3,5-difluoro, 2,6-difluoro, 1,2,3-trifluoro, 2,3,6-trifluoro, 2,4,6-trifluoro, 3,4,5-trifluoro, 2,3,5,6-tetrafluoro, 2,3,4,5,6-pentafluoro, azido, hexyl, t-butyl, phenyl, carboxyl, hydroxyl, methyoxy methoxy, phenyloxy, benzyloxy, phenylaminooxy, phenylaminocarbonyl, methyoxycarbonyl methoxycarbonyl, methylaminocarbonyl, dimethylamino, dimethylaminocarbonyl, or hydroxylaminocarbonyl group.
6. A compound of claim 3, wherein R4 is a hydrogen atom and R3 is a cyclohexyl group.
7. A compound of claim 3, wherein R4 is a hydrogen atom and R3 is a methyoxy methoxy group.
8. A compound of claim 3, wherein R3 and R4 bond together to form a piperidine group.
9. A compound of claim 3, wherein R4 is a hydrogen atom and R3 is a hydroxyl group.
10. A compound of claim 3, wherein R4 is a hydrogen atom and R3 is a benzyloxy group.
11. A compound of claim 3 2, wherein R4 is a hydrogen atom and R3 is a δ-pyridine γ-pyridine group.
12. A compound of claim 3 2, wherein R4 is a hydrogen atom and R3 is a β-pyridine group.
13. A compound of claim 3 2, wherein R4 is a hydrogen atom and R3 is a α-pyridine group.
14. A compound of claim 3, wherein R3 and R4 are both methyl groups.
15. A compound of claim 3, wherein R4 is a methyl group and R3 is a phenyl group.
16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 2.
17. A pharmaceutical composition of claim 16 in combination with an antitumor agent.
18. A compound having the structure:
Figure USRE038506-20040420-C00110
wherein n is an integer selected from the group consisting of 5, 6, 7 and 8.
19. A pharmaceutical composition comprising a therapeutically effective amount of a compound having the structure:
Figure USRE038506-20040420-C00111
wherein n is an integer selected from the group consisting of 5, 6, 7 and 8: and a pharmaceutically acceptable carrier.
20. A compound having the structure:
Figure USRE038506-20040420-C00112
21. A pharmaceutical composition comprising a therapeutically effective amount of a compound having the structure:
Figure USRE038506-20040420-C00113
and a pharmaceutically acceptable carrier.
22. A compound having the structure:
Figure USRE038506-20040420-C00114
23. A pharmaceutical composition comprising a compound having the structure:
Figure USRE038506-20040420-C00115
and a pharmaceutically acceptable carrier.
24. A compound having the structure:
Figure USRE038506-20040420-C00116
wherein R 3 is hydrogen and R 4 cycloalkyl, aryl, aryloxy, arylalkloxy, or pyridine group, or R 3 and R 4 bond together to form a piperidine group; R 2 is a hydroxylamino group; and n is an integer selected from the group consisting of 5, 6, 7 and 8.
US10004411 1991-10-04 2001-11-02 Potent inducers of terminal differentiation and methods of use thereof Expired - Lifetime USRE38506E1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US07771760 US5369108A (en) 1991-10-04 1991-10-04 Potent inducers of terminal differentiation and methods of use thereof
US10004411 USRE38506E1 (en) 1991-10-04 2001-11-02 Potent inducers of terminal differentiation and methods of use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10004411 USRE38506E1 (en) 1991-10-04 2001-11-02 Potent inducers of terminal differentiation and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07771760 Reissue US5369108A (en) 1991-10-04 1991-10-04 Potent inducers of terminal differentiation and methods of use thereof

Publications (1)

Publication Number Publication Date
USRE38506E1 true USRE38506E1 (en) 2004-04-20

Family

ID=32072620

Family Applications (1)

Application Number Title Priority Date Filing Date
US10004411 Expired - Lifetime USRE38506E1 (en) 1991-10-04 2001-11-02 Potent inducers of terminal differentiation and methods of use thereof

Country Status (1)

Country Link
US (1) USRE38506E1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072735A1 (en) * 2002-03-04 2004-04-15 Richon Victoria M. Methods of inducing terminal differentiation
US20040087631A1 (en) * 2002-03-04 2004-05-06 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid
US20060009526A1 (en) * 2002-02-15 2006-01-12 Richon Victoria M Method of treating TRX mediated diseases
US20060079551A1 (en) * 2001-10-16 2006-04-13 Richon Victoria M Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
US20080132575A1 (en) * 2005-05-20 2008-06-05 Jeannie Chow Wong Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same
US20080249179A1 (en) * 2002-03-04 2008-10-09 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20090012175A1 (en) * 2003-08-26 2009-01-08 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20090054720A1 (en) * 2002-04-15 2009-02-26 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
US7517701B2 (en) 2004-09-30 2009-04-14 Mds Analytical Technologies (Us) Inc. Luminescent lanthanide complexes
US20100113602A1 (en) * 2007-02-27 2010-05-06 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
US20100113392A1 (en) * 2006-11-03 2010-05-06 Badros Ashraf Z Methods of using saha and bortezomib for treating multiple myeloma
EP2236503A1 (en) 2009-04-03 2010-10-06 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US20100256401A1 (en) * 2009-04-03 2010-10-07 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2277387A1 (en) 2009-07-22 2011-01-26 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly
WO2011056542A1 (en) 2009-10-26 2011-05-12 Ramot At Tel-Aviv University Ltd. Cancer therapy with combinations of fts with hdac inhibitors
WO2012120262A1 (en) 2011-03-09 2012-09-13 Larsson Pia Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US9199923B2 (en) 2006-02-14 2015-12-01 President And Fellows Of Harvard College Histone deacetylase inhibitors
US9650379B2 (en) 2013-12-12 2017-05-16 Chong Kun Dang Pharmaceutical Corp. Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2279560A (en) 1940-05-08 1942-04-14 Du Pont Viscous hydrocarbon oil
US2279973A (en) 1940-05-08 1942-04-14 Du Pont Stabilization of organic substances
US2346665A (en) 1940-05-08 1944-04-18 Du Pont Acid
US2895991A (en) 1959-07-21 New chloromethylated amlides
US3450673A (en) 1965-09-07 1969-06-17 Ashland Oil Inc Polyurethane compositions from diaminimides
US3632783A (en) 1969-05-27 1972-01-04 Hall Co C P Treatment of mosquito bites employing certain tetraalkyl diamides
US3875301A (en) 1974-04-30 1975-04-01 Interx Research Corp Useful tetraalkyl diamides in the treatment of poison ivy
US4056524A (en) 1974-04-09 1977-11-01 Stauffer Chemical Company Bis-substituted succinamides and their utility as herbicides
US4442305A (en) 1981-08-24 1984-04-10 The United States Of America As Represented By The United States Department Of Energy Polycatecholamide chelating agents
EP0119428A2 (en) 1983-02-18 1984-09-26 Bayer Ag Biscarboxamides for treating diseases, and process for their preparation
US4480125A (en) 1981-11-16 1984-10-30 Polaroid Corporation Itaconamide compounds and method of preparation
US4537781A (en) 1983-09-16 1985-08-27 Research Corporation Pharmaceutically useful malonamides
DE3505250A1 (en) 1984-02-17 1985-09-12 Ppg Industries Inc Aliphatically unsaturated bis(polybromophenyl)diamides
US4611053A (en) 1985-02-15 1986-09-09 Sasa Michiyuki Mitch Polyhydroxamide polymer
US4614815A (en) 1979-09-10 1986-09-30 Anic S.P.A. Process for producing diesterdiamides
US4663353A (en) 1979-03-06 1987-05-05 The United States Of America As Represented By The Secretary Of Agriculture Antibacterial fatty anilides
US4801748A (en) 1985-03-08 1989-01-31 Osaka University Catalytic process for preparing amide from nitrile, amine and water
US4863967A (en) 1986-06-16 1989-09-05 Research Corporation N,N-diaminophthalamides
US4882346A (en) 1987-06-16 1989-11-21 The United States Of America As Reprsented By The Department Of Health And Human Services Chemical differentiating agents
GB2225012A (en) 1988-11-18 1990-05-23 Ibi Sued Spa Indole derivatives, their preparation and use as medicaments
WO1991000257A1 (en) 1989-06-30 1991-01-10 The Trustees Of Columbia University In The City Of New York Novel potent inducers of terminal differentiation and methods of use thereof
WO1991008191A1 (en) 1989-11-14 1991-06-13 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and method of use thereof
EP0433662A2 (en) 1989-11-16 1991-06-26 Warner-Lambert Company Acat inhibitors
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5098598A (en) 1988-12-24 1992-03-24 Interox Chemicals Limited Percarboxylic acids
EP0478954A1 (en) 1990-08-29 1992-04-08 Merrell Pharmaceuticals Inc. Serotonin 5HT1A and 5HT1D antagonists
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
EP0576941A1 (en) 1992-06-30 1994-01-05 Nisshin Flour Milling Co., Ltd. N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same
US5330744A (en) 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US5366982A (en) 1990-07-24 1994-11-22 Rhone-Poulenc Rorer S.A. Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene B4 antagonist activity, their preparation and use in pharmaceutical compositions

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2895991A (en) 1959-07-21 New chloromethylated amlides
US2279560A (en) 1940-05-08 1942-04-14 Du Pont Viscous hydrocarbon oil
US2279973A (en) 1940-05-08 1942-04-14 Du Pont Stabilization of organic substances
US2346665A (en) 1940-05-08 1944-04-18 Du Pont Acid
US3450673A (en) 1965-09-07 1969-06-17 Ashland Oil Inc Polyurethane compositions from diaminimides
US3632783A (en) 1969-05-27 1972-01-04 Hall Co C P Treatment of mosquito bites employing certain tetraalkyl diamides
US4056524A (en) 1974-04-09 1977-11-01 Stauffer Chemical Company Bis-substituted succinamides and their utility as herbicides
US3875301A (en) 1974-04-30 1975-04-01 Interx Research Corp Useful tetraalkyl diamides in the treatment of poison ivy
US4663353A (en) 1979-03-06 1987-05-05 The United States Of America As Represented By The Secretary Of Agriculture Antibacterial fatty anilides
US4614815A (en) 1979-09-10 1986-09-30 Anic S.P.A. Process for producing diesterdiamides
US4442305A (en) 1981-08-24 1984-04-10 The United States Of America As Represented By The United States Department Of Energy Polycatecholamide chelating agents
US4480125A (en) 1981-11-16 1984-10-30 Polaroid Corporation Itaconamide compounds and method of preparation
EP0119428A2 (en) 1983-02-18 1984-09-26 Bayer Ag Biscarboxamides for treating diseases, and process for their preparation
US4537781A (en) 1983-09-16 1985-08-27 Research Corporation Pharmaceutically useful malonamides
DE3505250A1 (en) 1984-02-17 1985-09-12 Ppg Industries Inc Aliphatically unsaturated bis(polybromophenyl)diamides
US4611053A (en) 1985-02-15 1986-09-09 Sasa Michiyuki Mitch Polyhydroxamide polymer
US4801748A (en) 1985-03-08 1989-01-31 Osaka University Catalytic process for preparing amide from nitrile, amine and water
US4863967A (en) 1986-06-16 1989-09-05 Research Corporation N,N-diaminophthalamides
US4882346A (en) 1987-06-16 1989-11-21 The United States Of America As Reprsented By The Department Of Health And Human Services Chemical differentiating agents
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5330744A (en) 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
GB2225012A (en) 1988-11-18 1990-05-23 Ibi Sued Spa Indole derivatives, their preparation and use as medicaments
US5098598A (en) 1988-12-24 1992-03-24 Interox Chemicals Limited Percarboxylic acids
WO1991000257A1 (en) 1989-06-30 1991-01-10 The Trustees Of Columbia University In The City Of New York Novel potent inducers of terminal differentiation and methods of use thereof
WO1991008191A1 (en) 1989-11-14 1991-06-13 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and method of use thereof
EP0433662A2 (en) 1989-11-16 1991-06-26 Warner-Lambert Company Acat inhibitors
US5366982A (en) 1990-07-24 1994-11-22 Rhone-Poulenc Rorer S.A. Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene B4 antagonist activity, their preparation and use in pharmaceutical compositions
EP0478954A1 (en) 1990-08-29 1992-04-08 Merrell Pharmaceuticals Inc. Serotonin 5HT1A and 5HT1D antagonists
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
EP0576941A1 (en) 1992-06-30 1994-01-05 Nisshin Flour Milling Co., Ltd. N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
Abstract for Accession No. 1966-26456F/196800 from, World Patent Index Database.
Abstract for Accession No. 1984-214010/198435 from, World Patent Index Database.
Abstract for Accession No. 1985-231331/198538 from Derwent Info Ltd.
Breslow, R., et al., "Potent Cytodifferentiating Agents Related to Hexamethylenebisacetamide," Proc. Natl. Acad. Sci. USA, 88:5542-5546 (1991).
Brown, D.A., "Design of Metal Chelates With Biological Activity. 5. Complexation Behavior of Dihydroxamic Acids with Metal Ions," American Chemical Society, 3729-3796 (1986).
Brown, D.A., et al., "A Facile Synthesis of Aliphatic Dihydroxamic Acids of General Formula RONR1-CO-(CH2)n-CO-NR1OR," Chem. Abs., 1986, 105, Abstract No. 78501v. (From Synth. Commun., 15(13):1159-1164, 1985).
Chugai Pharmaceutical Co., Ltd., "Benzenehydroxycarboxamides as Fumigant Insecticide Base Materials." (From 5-Agrochemicals, 1984, 101, Abstract No. 124925d).
Chun, J.G., et al., "Hexamethylene Bisacetamide: A Polar-Planar Compound Entering Clinical Trials as a Differentiating Agent," Cancer Treatment Reports, 70(8): 991-996 (1986).
Cleaver, C.S., and Pratt, B.C., "Synthesis of 2,2′-Bis-[5(4H)-oxazolones]," J. Amer. Chem. Soc., 77:1544 (1955).
Cleaver, C.S., and Pratt, B.C., "Synthesis of 2,2'-Bis-[5(4H)-oxazolones]," J. Amer. Chem. Soc., 77:1544 (1955).
Das, M.K., et al., "Synthesis of Some Dihydroxamic Acid Siderophores", Chem. Abs., 1984, 101, Abstract No. 54665t. (From J. Chem Eng. Data, 1984, 29(3):345-348, 1984.
Devlin, J.P., et al., "Studies Concerning the Antibiotic Actinonin. Part VI. Synthesis of Structural Analogues of Actinonin by Dicyclohexylcarbodi-imide Coupling Reactions," J. Chem. Soc. Perkins Trans. 1(9):848-851 (1975).
Endres, G.F. and J. Epstein, "Synthesis of Some Hydroxamic Acids. Reactivity with Isopropyl Methylphosphonofluoridate (GB)", J. Org. Chem., 24: 1497-1501 (1959).
Fibach, E., et al., "Effect of Hexamethylene Bisacetamide on the Commitment to Differentiation of Murine Erythroleukemia Cells," Cancer Research, 37:440-444 (1977).
Haces, A., et al., "Chemical Differentiating Agents. Differentiation of HL-60 Cells by Hexamethylenebis[acetamind] Angalogues," J. Med. Chem., 30:405-409 (1987).
Hill, J.W., and Carothers, W.H., "Studies of Polymerization and Ring Formation. XIX. Many-Membered Cyclic Anhydrides," J. Am. Chem. Soc., 55:5023-5031 (1933).
Hirom, P.C., et al., "Bile and Urine as Complementary Pathways for the Excretion of Foreign Organic Compounds," Xenobiotica, 6(1):55-64 (1976).
Hirom, P.C., et al., "Molecular Weight and Chemical Structure as Factors in the Biliary Excretion of Sulphonamides in the Rat," Xenobiotica, 2(3):205-214 (1972).
Hozumi, et al., "Induction of Erythroid Differentiation in Murine Erythroleukemia Cells by N-Substituted Polymethylene Diamides," Int. J. Cancer, 23:119-122 (1979).
Hynes, J.B., "Hydroxylamine Derivatives as Potential Antimalarial Agents. 1. Hydroxamic Acids1." J. Med. Chem., 13(6):1235-1237 (1970).
Linfield, W.M., et al., "Antibacterially Active Substituted Anilides of Carboxylic and Sulfonic Acids," J. Med. Chem., 26:1741-1746 (1983).
Lion, C., et al., "Synthese Dans La Chimie Des Phenanthridines. II. Preparation D'Une Nouvelle Serie D'omega-(Phenanthridinyl-6) Alcanoates De Methyle Ou D'Ethyle," Bull. Soc. Chim. Belg., 98(8):567-573 (1989).
Lion, C., et al., "Synthese Dans La Chimie Des Phenanthridines. II. Preparation D'Une Nouvelle Serie D'ω-(Phenanthridinyl-6) Alcanoates De Methyle Ou D'Ethyle," Bull. Soc. Chim. Belg., 98(8):567-573 (1989).
Lion, C., et al., "Synthese Dans La Chimie Des Phenanthridines. III. Preparation De Quelques Modeles D'Acides omega-(Diamino -3,8 Phenanthridinyl-6) Carboxyliques," Bull. Soc. Chim. Belg., 99(3):171-181 (1990).
Lion, C., et al., "Synthese Dans La Chimie Des Phenanthridines. III. Preparation De Quelques Modeles D'Acides ω-(Diamino -3,8 Phenanthridinyl-6) Carboxyliques," Bull. Soc. Chim. Belg., 99(3):171-181 (1990).
Marks, P.A., et al., "Polar/apolar Chemical Inducers of Differentiation of Transformed Cells: Strategies to Improve Therapeutic Potential," Proc. Natl. Acad. Sci., 86:6358-6362 (1989).
Melloni, E., et al., "Vincristine-resistant Erythroleukemia Cell Line Has Markedly Increased Sensitivity to Hexamethylenebisacetamide-Induced Differentiation." Chem. Abs., 1988, 109, Abstract No. 47737e. (From Proc. Natl. Acad. Sci. USA, 85(11):3835-3839, 1988).
Morrison, R. T., and Boyd, R.N., "Conversion of Amines Into Substituted Amides." In Organic Chemistry (3rd ed.), Allyn and Bacon, Inc., Boston, p. 755 (1973).
Mueller, G., et al., "Coordination Chemistry of Microbial Iron Transport Compounds. 31. The Mechanism and Specificity of Iron Transport in Rhodotorula Pilimanae Probed by Synthetic Analogs of Rhodotorulic Acid." (From Chem. Abs., 1985, 103, Abstract No. 192908s.
Paolini, J.P., et al., "N<4>,N<4'>-Decamethylenebis-4-aminopyridine and N<9>,N<9'>-Decamethylenebis-9-aminoacridine," J. Med. Chem., 12(4):701 (1969).
Paolini, J.P., et al., "N4,N4′-Decamethylenebis-4-aminopyridine and N9,N9′-Decamethylenebis-9-aminoacridine," J. Med. Chem., 12(4):701 (1969).
Prabhakar, Y.S., et al., "Quantitative Correlations of Biological Activities of Dactinomycin Analogs and Methotrexate Derivatives with Van Der Waals Volume," Birla Institute of Technology and Science, Pilani (India), pp. 1030-1033.
Reuben, R.C., et al., "Inducers of Erythroleukemic Differentiation," J. Biolog. Chem., 253:4214-4218 (1978).
Tabernero, E., et al., "Antitrypanosomal (T. Venezuelense) and Antimycotic Effect of Various Hydroxamic Acids," Chem. Abs., 1983, 98, Abstract No. 191329v. (From Acta. Cient. Venez., 32(5):411-416, 1981).
Tanaka, M., et al., "Induction of Erythroid Differentiation in Murine Virus Infected Erythroleukemia Cells By Highly Polar Compounds," Proc. Natl. Acad. Sci., 72(3):1003-1006 (1975).
Weitl, F.L., and Raymond, K.N., "Lipophilic Enterobactin Analogues Terminally N-Alkylated Spermine/Spermidine Catecholcarboxamides," J. Org. Chem., 46:5234-5237 (1981).
Wojcik, A., and, Adkins, H., "Catalytic Hydrogenation of Amides to Amines," J. Amer. Chem. Soc., 56:2419 (1932).

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879865B2 (en) 2001-10-16 2011-02-01 Sloan-Kettering Institute For Cancer Research Treatment of cancer of the brain using histone deacetylase inhibitors
US20110124731A1 (en) * 2001-10-16 2011-05-26 Sloan-Kettering Institute For Cancer Research Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors
US20060079551A1 (en) * 2001-10-16 2006-04-13 Richon Victoria M Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US20060009527A1 (en) * 2002-02-15 2006-01-12 Richon Victoria M Method of treating TRX mediated diseases
US20060009526A1 (en) * 2002-02-15 2006-01-12 Richon Victoria M Method of treating TRX mediated diseases
US20100168242A1 (en) * 2002-03-04 2010-07-01 Miller Thomas A Polymorphs of suberoylanilide hydroxamic acid
US20040127522A1 (en) * 2002-03-04 2004-07-01 Chiao Judy H. Methods of treating cancer with HDAC inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid
US8101663B2 (en) 2002-03-04 2012-01-24 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20080114069A1 (en) * 2002-03-04 2008-05-15 Richon Victoria M Methods of inducing terminal differentiation
US7375137B2 (en) 2002-03-04 2008-05-20 Merck Hdac Research, Llc Methods of treating cancer with HDAC inhibitors
US20040087631A1 (en) * 2002-03-04 2004-05-06 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7399787B2 (en) 2002-03-04 2008-07-15 Merck Hdac Research, Llc Methods of treating cancer with HDAC inhibitors
US20080194692A1 (en) * 2002-03-04 2008-08-14 Miller Thomas A Polymorphs of suberoylanilide hydroxamic acid
US20080228005A1 (en) * 2002-03-04 2008-09-18 Miller Thomas A Polymorphs of suberoylanilide hydroxamic acid
US20080249179A1 (en) * 2002-03-04 2008-10-09 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7851509B2 (en) 2002-03-04 2010-12-14 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7847122B2 (en) 2002-03-04 2010-12-07 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7652069B2 (en) 2002-03-04 2010-01-26 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040072735A1 (en) * 2002-03-04 2004-04-15 Richon Victoria M. Methods of inducing terminal differentiation
US20090054720A1 (en) * 2002-04-15 2009-02-26 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
US20090012175A1 (en) * 2003-08-26 2009-01-08 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7517701B2 (en) 2004-09-30 2009-04-14 Mds Analytical Technologies (Us) Inc. Luminescent lanthanide complexes
US8450372B2 (en) 2005-05-20 2013-05-28 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
US8093295B2 (en) 2005-05-20 2012-01-10 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing the same
US20100119596A1 (en) * 2005-05-20 2010-05-13 Jeannie Chow Wong Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20080132575A1 (en) * 2005-05-20 2008-06-05 Jeannie Chow Wong Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same
US8288440B2 (en) 2005-05-20 2012-10-16 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
US20090247549A1 (en) * 2005-11-04 2009-10-01 Frankel Stanley R Methods of using saha and bortezomib for treating cancer
US9724321B2 (en) 2006-02-14 2017-08-08 President & Fellows Of Harvard College Histone deacetylase inhibitors
US9199923B2 (en) 2006-02-14 2015-12-01 President And Fellows Of Harvard College Histone deacetylase inhibitors
US20100113392A1 (en) * 2006-11-03 2010-05-06 Badros Ashraf Z Methods of using saha and bortezomib for treating multiple myeloma
US20100113602A1 (en) * 2007-02-27 2010-05-06 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
US7994357B2 (en) 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2236503A1 (en) 2009-04-03 2010-10-06 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US20100256401A1 (en) * 2009-04-03 2010-10-07 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2277387A1 (en) 2009-07-22 2011-01-26 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly
WO2011056542A1 (en) 2009-10-26 2011-05-12 Ramot At Tel-Aviv University Ltd. Cancer therapy with combinations of fts with hdac inhibitors
WO2012120262A1 (en) 2011-03-09 2012-09-13 Larsson Pia Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US9650379B2 (en) 2013-12-12 2017-05-16 Chong Kun Dang Pharmaceutical Corp. Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same

Similar Documents

Publication Publication Date Title
US5879681A (en) Compounds and compositions for delivering active agents
US5876710A (en) Compounds and compositions for delivering active agents
US4980502A (en) Paramagnetic chelates
US6242495B1 (en) Compounds and compositions for delivering active agents
US6310059B1 (en) Fused ring calcium channel blockers
USRE38551E1 (en) Anticonvulsant enantiomeric amino acid derivatives
US6051561A (en) Compounds and compositions for delivering active agents
US5322679A (en) Iodinated aroyloxy esters
US6060513A (en) Compounds and compositions for delivering active agents
US6395774B1 (en) Carbon-substituted diketopiperazine delivery systems
US5242944A (en) Phenylacetamide derivatives and pharmaceutical compositions thereof
US5804688A (en) Compounds and compositions for delivering active agents
US6090958A (en) Compounds and compositions for delivering active agents
US6525020B2 (en) Compounds and compositions for delivering active agents
US5773475A (en) Anticonvulsant enantiomeric amino acid derivatives
US6048899A (en) Anticonvulsant enantiomeric amino acid derivatives
US6310060B1 (en) 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
Breslow et al. Potent cytodifferentiating agents related to hexamethylenebisacetamide.
US20030191323A1 (en) Hypoglycemic agent
US4751244A (en) Compounds useful in treating sickle cell anemia
US20090036420A1 (en) Benzamide derivatives and their use for treating cns disorders
US4478836A (en) 1-Aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives and their use as useful drugs in the treatment of disturbances of the central nervous system
US20050239740A1 (en) Hydrazide-containing CFTR inhibitor compounds and uses thereof
US6589986B2 (en) Methods of treating anxiety disorders
US5863944A (en) Compounds and compositions for delivering active agents

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12

CC Certificate of correction
PTEF Application for a patent term extension

Free format text: PRODUCT NAME: ZOLINZA (VORINOSTAT, SUBEROYLANILIDE HYDROXAMIC ACID); REQUESTED FOR 1433 DAYS

Filing date: 20061202

Expiry date: 20111129

PTEG Grant of a patent term extension

Free format text: PRODUCT NAME: ZOLINZA (VORINOSTAT, SUBEROYLANILIDE HYDROXAMIC ACID)

Filing date: 20061202

Expiry date: 20111129